GBS and Menactra® Meningococcal Vaccine
Between 2005 and 2008, there were concerns that the meningococcal vaccine Menactra caused a serious neurological disorder called Guillain-Barré Syndrome (GBS). There were a number of youth who reported GBS after receiving Menactra. This page answers questions pertaining to this issue.
- Does Menactra Meningococcal Conjugate Vaccine cause Guillain-Barré Syndrome (GBS)?
- What is GBS?
- What causes GBS?
- Have other vaccines ever been suspected of causing GBS?
- Where can I get more information about meningococcal vaccines?
- How can I report a case of GBS after Menactra or any vaccine?
No. Two large studies were conducted to investigate whether GBS was caused by the vaccine or was coincidental with vaccination. These studies included a combined total of over 2 million vaccinated adolescents. The results of these studies showed that there was no link between Menactra and GBS.
- A 2012 study used health records of over 9.6 million preteens and teens to evaluate a possible link between Menactra and GBS. The study found that youth who received Menactra were not at increased risk of developing GBS.
- Another large 2012 study combined the above study with data from the Vaccine Safety Datalink to search for diagnoses of GBS in 11.2 million preteens and teens who received Menactra. This study also found no link between GBS and Menactra and observed 0 confirmed GBS cases.
GBS is a rare disorder in which a person’s own immune system damages their nerve cells, causing muscle weakness and sometimes paralysis. It often follows infection with a virus or bacteria. Most people recover fully from GBS, but some people have permanent nerve damage. In the United States, an estimated 3,000 to 6,000 people develop GBS each year, whether or not they received a vaccination. For more information on GBS, visit: http://www.cdc.gov/vaccinesafety/Concerns/gbs.html.
Many things can cause GBS, including common infections such as sore throats and other infections that occur in the community.
In 1976, flu vaccine was associated with a rare risk of GBS. The Institute of Medicine (IOM) conducted a thorough scientific review of this issue in 2003 and concluded that people who received the 1976 swine influenza vaccine had an increased risk for developing GBS. Scientists have multiple theories on why this increased risk may have occurred, but the exact reason for this association remains unknown.
More information is available on CDC’s Meningococcal Vaccination webpage.
Any possible vaccine side effect can be reported to the Vaccine Adverse Event Reporting System (VAERS) to help CDC and the Food and Drug Administration better understand vaccine safety. Anyone can report to VAERS online at www.vaers.hhs.gov or by phone at 1-800-822-7967.
Related Scientific Articles
CDC. Guillain-Barré Syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June-July 2005. MMWR. 2005 Oct 6:54(Dispatch);1-3.
CDC. Update: Guillain-Barré Syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, October 2005-February 2006. MMWR. 2006 Apr 7:(55(13);364-366.
CDC. Update: Guillain-Barré Syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006. MMWR. 2006 Oct 20:55(41);1120-1124.
Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, et al. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf. 2012 Dec;21(12):1350-8. Epub 2012 Jul 16.
Yih WK, Weintraub E, Kulldorff M. No risk of Guillain-Barré syndrome found after meningococcal conjugate vaccination in two large cohort studies. Pharmacoepidemiol Drug Saf. 2012 Dec;21(12):1359-60.
- Frequently Asked Questions about Guillain-Barré Syndrome and Menactra® Meningococcal Vaccine
- Guillain-Barré Syndrome
- Vaccine Adverse Event Reporting System